Literature DB >> 19020201

Impact of respiratory syncytial virus in the United States.

Renee F Robinson1.   

Abstract

PURPOSE: Respiratory syncytial virus (RSV) infection is most common in infants and young children, with almost all children experiencing at least one infection by their second birthday.
SUMMARY: RSV is the leading cause of upper and lower respiratory tract infections in infants and young children, and is the most common cause of bronchiolitis and pneumonia in children younger than one year of age. Since infection with RSV does not result in permanent immunity, repeat infections are common, often occurring during the same RSV season. RSV bronchiolitis is the leading cause of hospitalization in children younger than age one, and this virus is associated with approximately 75,000 to 125,000 hospitalizations annually in the United States. Children hospitalized for RSV bronchiolitis during the first year of life are at an increased risk of respiratory problems, such as wheezing and allergic asthma, throughout childhood and into adolescence. RSV-related mortality has decreased over the last 20 years; however, RSV is still the leading cause of viral deaths in infants.
CONCLUSION: RSV infection is associated with significant disease burden in infants and young children in terms of hospitalization, related complications, and even mortality. The economic burden resulting from RSV disease is also substantial, with significantly higher costs seen in children with risk factors for severe disease and RSV-related complications.

Entities:  

Mesh:

Year:  2008        PMID: 19020201     DOI: 10.2146/ajhp080438

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  15 in total

1.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter.

Authors:  Sarah L Noton; Kartikeya Nagendra; Ewan F Dunn; Michael E Mawhorter; Qin Yu; Rachel Fearns
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis.

Authors:  Carolina Scagnolari; Fabio Midulla; Alessandra Pierangeli; Corrado Moretti; Enea Bonci; Rosaria Berardi; Daniela De Angelis; Carla Selvaggi; Paola Di Marco; Enrico Girardi; Guido Antonelli
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

3.  Upregulation of H3K27 Demethylase KDM6 During Respiratory Syncytial Virus Infection Enhances Proinflammatory Responses and Immunopathology.

Authors:  Carrie-Anne Malinczak; Andrew J Rasky; Wendy Fonseca; Matthew A Schaller; Ronald M Allen; Catherine Ptaschinski; Susan Morris; Nicholas W Lukacs
Journal:  J Immunol       Date:  2019-11-20       Impact factor: 5.422

4.  Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis.

Authors:  Ângela Esposito Ferronato; Alfredo Elias Gilio; Alexandre Archanjo Ferraro; Milena de Paulis; Sandra E Vieira
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

Review 5.  Treatment of respiratory syncytial virus with palivizumab: a systematic review.

Authors:  Jia Hu; Joan L Robinson
Journal:  World J Pediatr       Date:  2010-11-16       Impact factor: 9.186

6.  High rate of viral identification and coinfections in infants with acute bronchiolitis.

Authors:  Milena Siciliano Nascimento; Andréa Vieira de Souza; Adriana Vada de Souza Ferreira; Joaquim Carlos Rodrigues; Sulim Abramovici; Luiz Vicente Ferreira da Silva Filho
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

7.  Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease.

Authors:  Sol Kim; Jun Chang
Journal:  Immune Netw       Date:  2012-02-29       Impact factor: 6.303

8.  Acute lower respiratory tract infection due to respiratory syncytial virus in a group of Egyptian children under 5 years of age.

Authors:  Aya M Fattouh; Yasmeen A Mansi; Mervat G El-Anany; Amany A El-Kholy; Hanaa M El-Karaksy
Journal:  Ital J Pediatr       Date:  2011-04-06       Impact factor: 2.638

Review 9.  New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.

Authors:  Nicolás M S Gálvez; Jorge A Soto; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

10.  Characteristics of children admitted to intensive care with acute bronchiolitis.

Authors:  Marwa Ghazaly; Simon Nadel
Journal:  Eur J Pediatr       Date:  2018-04-13       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.